middle.news
Vectus Turns XORTX Deal Into $1.56m Profit as VB0004 Advances
2:01pm on Friday 18th of September, 2026 AEST
•
Biotechnology
Read Story
Vectus Turns XORTX Deal Into $1.56m Profit as VB0004 Advances
2:01pm on Friday 18th of September, 2026 AEST
Key Points
FY2026 profit of $1.56 million versus a restated $1.86 million loss
$2.55 million net gain from the VB4-P5 transaction with XORTX
VB0004 targeted for a Phase Ib trial in idiopathic pulmonary fibrosis
$718,594 cash balance after $573,395 operating cash burn
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vectus Biosystems (ASX:VBS)
OPEN ARTICLE